Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer

To explore the signature function of the tumor mutational burden (TMB) and potential biomarkers in prostate cancer (PCa), transcriptome profiles, somatic mutation data, and clinicopathologic feature information were downloaded from The Cancer Genome Atlas (TCGA) database. R software package was used...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Licheng Wang MM, Yicong Yao MM, Chengdang Xu MM, Xinan Wang MM, Denglong Wu MD, PhD, Zhe Hong MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1475b158b2494224bfbaa17f3c4d00ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1475b158b2494224bfbaa17f3c4d00ac
record_format	dspace
spelling	oai:doaj.org-article:1475b158b2494224bfbaa17f3c4d00ac2021-11-21T02:04:51ZExploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer1533-033810.1177/15330338211052154https://doaj.org/article/1475b158b2494224bfbaa17f3c4d00ac2021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211052154https://doaj.org/toc/1533-0338To explore the signature function of the tumor mutational burden (TMB) and potential biomarkers in prostate cancer (PCa), transcriptome profiles, somatic mutation data, and clinicopathologic feature information were downloaded from The Cancer Genome Atlas (TCGA) database. R software package was used to generate a waterfall plot to summarize the specific mutation information and calculate the TMB value of PCa. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis was used to select the hub genes related to the TMB from the ImmPort network to build a risk score (RS) model to evaluate prognostic values and plot Kaplan–Meier (K-M) curves to predict PCa patients survival. The results showed that PCa patients with a high TMB exhibited higher infiltration of CD8+ T cells and CD4+ T cells and better overall survival (OS) than those with a low TMB. The anti-Mullerian hormone (AMH), baculoviral IAP repeat-containing 5 (BIRC5), and opoid receptor kappa 1 (OPRK1) genes were three hub genes and their copy number variation (CNV) was relatively likely to affect the infiltration of immune cells. Moreover, PCa patients with low AMH or BIRC5 expression had a longer survival time and lower cancer recurrence, while elevated AMH or BIRC5 expression favored PCa progression. In contrast, PCa patients with low OPRK1 expression had poorer OS in the early stage of PCa and a higher recurrent rate than those with high expression. Taken together, these results suggest that the TMB may be a promising prognostic biomarker for PCa and that AMH, OPRK1, and BIRC5 are hub genes affecting the TMB; AMH, OPRK1, and BIRC5 could serve as potential immunotherapeutic targets for PCa treatment.Licheng Wang MMYicong Yao MMChengdang Xu MMXinan Wang MMDenglong Wu MD, PhDZhe Hong MD, PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Licheng Wang MM Yicong Yao MM Chengdang Xu MM Xinan Wang MM Denglong Wu MD, PhD Zhe Hong MD, PhD Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
description	To explore the signature function of the tumor mutational burden (TMB) and potential biomarkers in prostate cancer (PCa), transcriptome profiles, somatic mutation data, and clinicopathologic feature information were downloaded from The Cancer Genome Atlas (TCGA) database. R software package was used to generate a waterfall plot to summarize the specific mutation information and calculate the TMB value of PCa. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis was used to select the hub genes related to the TMB from the ImmPort network to build a risk score (RS) model to evaluate prognostic values and plot Kaplan–Meier (K-M) curves to predict PCa patients survival. The results showed that PCa patients with a high TMB exhibited higher infiltration of CD8+ T cells and CD4+ T cells and better overall survival (OS) than those with a low TMB. The anti-Mullerian hormone (AMH), baculoviral IAP repeat-containing 5 (BIRC5), and opoid receptor kappa 1 (OPRK1) genes were three hub genes and their copy number variation (CNV) was relatively likely to affect the infiltration of immune cells. Moreover, PCa patients with low AMH or BIRC5 expression had a longer survival time and lower cancer recurrence, while elevated AMH or BIRC5 expression favored PCa progression. In contrast, PCa patients with low OPRK1 expression had poorer OS in the early stage of PCa and a higher recurrent rate than those with high expression. Taken together, these results suggest that the TMB may be a promising prognostic biomarker for PCa and that AMH, OPRK1, and BIRC5 are hub genes affecting the TMB; AMH, OPRK1, and BIRC5 could serve as potential immunotherapeutic targets for PCa treatment.
format	article
author	Licheng Wang MM Yicong Yao MM Chengdang Xu MM Xinan Wang MM Denglong Wu MD, PhD Zhe Hong MD, PhD
author_facet	Licheng Wang MM Yicong Yao MM Chengdang Xu MM Xinan Wang MM Denglong Wu MD, PhD Zhe Hong MD, PhD
author_sort	Licheng Wang MM
title	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
title_short	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
title_full	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
title_fullStr	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
title_full_unstemmed	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
title_sort	exploration of the tumor mutational burden as a prognostic biomarker and related hub gene identification in prostate cancer
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/1475b158b2494224bfbaa17f3c4d00ac
work_keys_str_mv	AT lichengwangmm explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer AT yicongyaomm explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer AT chengdangxumm explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer AT xinanwangmm explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer AT denglongwumdphd explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer AT zhehongmdphd explorationofthetumormutationalburdenasaprognosticbiomarkerandrelatedhubgeneidentificationinprostatecancer
_version_	1718419348053295104

Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer

Ejemplares similares